One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible
For decades, heart disease has been the number one killer worldwide, impacting millions of lives annually and placing a significant strain on healthcare systems around the world.
Physicians have long used lifestyle modifications, cholesterol-lowering statins, blood pressure drugs and surgeries to diminish the chances of a heart attack or stroke. These treatments have helped many people survive, but they typically need to be taken for life, take pills every day, repeat shots and have regular check-ups with medical providers. Now, a new generation of scientific research is raising the excitement that a single treatment could dramatically lower the risk of heart disease. Researchers working on cutting-edge gene-editing tools like CRISPR are developing therapies that could keep potentially deadly cholesterol levels down permanently, by infusing a single time. Initial research indicates this “one-and-done” approach could eventually become the standard care for some individuals instead of medication that they take for years, and could change prevention cardiology forever. It all sounds futuristic, but it's already happening, and the first preliminary outcomes are promising. These therapies are intended to "turn off" individual genes in the liver that generate proteins associated with high cholesterol and cardiovascular disease, according to researchers. Scientists hope to make permanent changes to these genes that will lead to decreased levels of harmful blood fats which over time damage artery walls. This new but popular topic has been gaining momentum worldwide since cardiovascular disease is still the leading cause of death for people around the world, more than cancer and many other significant diseases. Despite the availability of modern medicines, millions of patients remain difficult to manage for their cholesterol level and/or forget to take them regularly. Some people give up on treatment due to side effects and some people forget to take their pills on a regular basis. If scientists continue to find the therapy safe and effective, gene-editing technology could help address many of these issues. However, recent clinical trials have demonstrated that a single infusion of CRISPR was able to successfully reduce low-density lipoprotein cholesterol, also known as LDL or “bad” cholesterol, by approximately 50% in some patients. These studies also showed a very significant reduction in another key cardiovascular risk factor – triglycerides. These benefits were seen in fewer weeks after the treatment and continued throughout follow-up time. (American Heart Association)
These therapies are complicated and revolutionary science. CRISPR is like a set of molecular scissors that can precisely edit certain parts of DNA. Researchers are working on genes that regulate the production of cholesterol within the liver in studies of heart disease. An important target is the PCK9 gene which affects the amount of LDL cholesterol in the bloodstream. The other promising target is the gene ANGPTL3, which is linked to cholesterol and triglyceride levels. Certain people are born with the mutations that stop these genes from working, and researchers noticed that these people have very low cholesterol levels throughout their lives, and fewer heart disease. Based on this observation, researchers began to ask the big question: what if they could mimic these protective genetic effects in patients who have a higher risk of cardiovascular disease? Rather than repeatedly treating symptoms for decades, researchers are hoping to permanently alter the underlying biological processes that cause the accumulation of cholesterol that can lead to disease. Experimental therapies include the direct delivery of the CRISPR editing machinery into liver cells via tiny fat-based particles called lipid nanoparticles. The gene-editing system inside the liver makes targeted changes that would turn off the production of harmful proteins. The liver sits on top of these pathways and is constantly monitoring the blood cholesterol, which means that blood cholesterol levels may be permanently protected. This is a paradigm shift from traditional medicine to genetic prevention, scientists say. The method is similar to a cure as opposed to a temporary fix as the edited genes can potentially continue to function in a different way for years or even indefinitely. (Nature)
An experimental CRISPR-Cas9 therapy called CTX310 was one of the biggest recent advances in Phase 1 clinical trials of a first-in-human study. The results were shared at the American Heart Association Scientific Sessions and published at the same time in a peer-reviewed medical journal. Patients in the trial had undergone treatment with the maximum dose of standard cholesterol medications but still had dangerous levels of cholesterol. The one-timer infusion group had significantly lower levels of the 'bad' cholesterol, LDL, and triglycerides, the scientists said. In higher doses, LDL cholesterol decreased by almost 50 percent, and triglyceride levels decreased by nearly 55 percent. Additionally, these decreases were found to occur within two weeks, and to be stable throughout the period of follow-up in the study, researchers said. Most importantly, the therapy did not seem to be harmful in this small, preliminary study. Some participants had slight temporary reactions, including nausea or back pain, and one participant reported transient elevations in liver enzymes which returned to normal without treatment. Scientists said more long-term studies were still required as gene editing involves changes to the DNA which will be permanent and there could be unforeseen effects or side effects in the future. Many cardiologists, however, were amazed by the results, calling them "very promising" because the treatment was biologically active and yielded "manageable short-term safety results" in the first human trial. (American Heart Association)
Another company pushing the field forward is Verve Therapeutics, which has been developing gene-editing therapies aimed at permanently reducing cholesterol through PCSK9 modification. Verve’s experimental treatments use a form of gene editing called base editing, which differs slightly from traditional CRISPR-Cas9 systems. Instead of cutting both strands of DNA, base editing changes a single DNA letter, potentially reducing the risk of unintended genetic damage. Scientists believe this technique may provide greater precision and safety for long-term therapies. Early studies involving Verve’s VERVE-101 and VERVE-102 treatments showed significant LDL cholesterol reductions in patients with inherited cholesterol disorders and premature coronary artery disease. Some participants experienced LDL reductions exceeding 50%, and researchers reported encouraging safety profiles during preliminary follow-up. The therapy is particularly important for people with familial hypercholesterolemia, a genetic condition causing extremely high cholesterol levels from birth. Many patients with this disorder develop heart disease at relatively young ages even when they take strong medications. Researchers hope gene-editing therapy could offer these individuals a more durable solution than lifelong drug treatment. Pharmaceutical companies and investors are increasingly interested in this technology because of its enormous commercial and medical potential. Eli Lilly’s multibillion-dollar acquisition agreement involving Verve Therapeutics reflected growing confidence that gene editing could eventually reshape cardiovascular medicine. (Nature)
Despite the excitement, scientists repeatedly stress that these treatments are still experimental and far from becoming widely available to the public. The current studies involve only small numbers of patients, and researchers still need years of additional testing before regulators can determine whether the therapies are truly safe and effective. Gene editing creates permanent biological changes, meaning mistakes or unexpected side effects could potentially last a lifetime. One of the biggest concerns involves “off-target” edits, where CRISPR accidentally modifies DNA in unintended locations. Such changes could theoretically trigger dangerous complications including cancer, immune problems, or organ damage. Scientists are therefore proceeding very cautiously. Regulatory agencies require extensive evidence before approving permanent genetic therapies for widespread use. Researchers must also determine whether cholesterol reductions remain stable for many years and whether the treatment actually prevents heart attacks, strokes, and deaths in large populations. Lower cholesterol numbers are encouraging, but the ultimate goal is reducing cardiovascular events and extending healthy life expectancy. Long-term monitoring is especially important because some gene-editing therapies in other medical fields have faced serious safety issues. Experts emphasize that no one should view these treatments as ready replacements for proven therapies like statins, exercise, and healthy diets. For now, traditional cardiovascular prevention remains essential. (AP News)
The reason scientists are so motivated to develop one-time cardiovascular treatments is because adherence to existing therapies remains a major global challenge. Millions of patients are prescribed cholesterol-lowering drugs every year, yet many fail to take them consistently. Studies repeatedly show that medication noncompliance significantly increases the risk of heart attacks and strokes. Some patients experience muscle pain or other side effects from statins, while others struggle with the cost or inconvenience of long-term treatment. Injectable cholesterol-lowering drugs such as PCSK9 inhibitors can be highly effective, but they often require repeated dosing and can be expensive. Public health experts believe a single long-lasting therapy could dramatically improve prevention if it proves safe. Instead of relying on daily patient behavior for decades, doctors might someday administer a one-time treatment that permanently lowers cardiovascular risk. Researchers compare this possibility to vaccines that protect people against infectious diseases for many years after a single series of injections. If successful, gene editing could eventually become part of preventive medicine strategies for high-risk populations. However, experts caution that widespread use would likely begin with patients who face the greatest danger from inherited cholesterol disorders or severe cardiovascular disease before expanding to broader groups. (American Heart Association)
The broader field of cardiovascular genetics is advancing rapidly beyond cholesterol management alone. Scientists are exploring gene therapies for inherited heart muscle diseases, heart failure caused by amyloid protein buildup, and other serious cardiovascular disorders. Researchers believe precision medicine may eventually allow doctors to tailor treatments according to each patient’s genetic profile. Advances in artificial intelligence, molecular biology, and genome sequencing are accelerating discovery in this area. Just a decade ago, gene editing in humans sounded like science fiction to many people. Today, several CRISPR-based therapies are already approved for other diseases, including sickle cell disease. This growing success increases confidence that cardiovascular applications may eventually reach clinical practice as well. However, heart disease presents unique challenges because it affects enormous populations, including otherwise healthy individuals who may only face elevated future risk. Safety standards for preventive therapies must therefore remain exceptionally high. Doctors must be certain that long-term benefits clearly outweigh potential risks before offering permanent genetic treatments to large numbers of people. (Harvard Health)
Another important factor driving interest in one-and-done heart disease prevention is the growing understanding of how genetics influence cholesterol levels. Many people assume high cholesterol is caused mainly by poor diet or lack of exercise, but genetics play a major role in determining cardiovascular risk. Some individuals inherit conditions that keep LDL cholesterol extremely high even when they maintain healthy lifestyles. Familial hypercholesterolemia is one example, affecting millions of people worldwide. Patients with this condition may develop severe artery plaque buildup decades earlier than average. Gene-editing therapies are especially appealing for such patients because they target the root biological mechanisms causing disease rather than merely controlling symptoms temporarily. Researchers studying natural genetic mutations discovered that people lacking functional PCSK9 or ANGPTL3 genes often experience lifelong protection against cardiovascular disease without obvious harmful consequences. These observations provided strong scientific justification for developing therapies that intentionally disable the same genes in high-risk patients. (Nature)
Public reaction to these breakthroughs has been a mix of excitement, curiosity, and caution. Many patients living with severe cholesterol disorders express hope that future therapies could free them from lifelong medication routines and constant fear of heart disease. Online discussions show strong interest from people who struggle with inherited high cholesterol despite healthy lifestyles. At the same time, others worry about the ethical and medical implications of permanently altering human DNA. Some experts believe society will need careful public conversations about cost, accessibility, long-term monitoring, and informed consent before such treatments become mainstream. Gene-editing therapies are expected to be extremely expensive initially, potentially limiting access for lower-income populations unless healthcare systems develop broader coverage strategies. Questions also remain about whether these therapies might eventually be used preventively in otherwise healthy younger adults who have elevated genetic risk scores but no active disease. (Reddit)
Even as researchers pursue futuristic therapies, doctors continue emphasizing the importance of traditional heart disease prevention. Healthy eating, regular physical activity, weight management, avoiding smoking, controlling diabetes, and maintaining healthy blood pressure remain critical pillars of cardiovascular health. Experts warn that no emerging therapy should encourage people to ignore lifestyle habits that protect the heart. Even if gene editing eventually lowers cholesterol permanently, cardiovascular disease involves many interconnected risk factors including inflammation, obesity, stress, and metabolic disorders. Current guidelines also encourage regular cholesterol screening and better identification of inherited cardiovascular risk factors. Medical organizations increasingly recommend testing for lipoprotein(a), another genetically influenced cholesterol-related risk factor associated with heart disease. Advances in prevention science are helping doctors identify danger earlier and intervene more aggressively before irreversible artery damage occurs. (Health)
The future of one-and-done heart disease prevention will depend heavily on the outcomes of larger and longer clinical trials over the next several years. Researchers must answer many critical questions before these therapies can become standard medical care. Scientists need to confirm that gene editing remains accurate and stable long term, determine whether repeated treatments might ever be necessary, and establish how different patient populations respond to therapy. Regulatory approval will likely require evidence from thousands of participants followed over many years. Even then, doctors may initially reserve these treatments for patients with the highest cardiovascular risk or inherited lipid disorders before expanding access gradually. Still, the progress achieved so far represents one of the most exciting developments in modern cardiovascular medicine. For decades, prevention strategies focused mainly on lifelong management rather than permanent biological correction. Gene editing introduces a fundamentally different approach that attempts to reprogram disease pathways directly at the genetic level. If future studies continue producing positive results, medicine could move closer to an era where certain forms of heart disease prevention require only a single carefully designed treatment instead of decades of medication and monitoring. (American Heart Association)
Scientists are careful not to promise miracles too early, but many agree that the field has entered a historic turning point. Early CRISPR cholesterol studies have already demonstrated something that once seemed impossible: the ability to permanently alter genes inside the human body in ways that significantly reduce dangerous blood fats associated with heart disease. The findings remain preliminary, and major scientific challenges still exist, but the potential impact is enormous. Heart disease continues to kill millions worldwide each year despite decades of medical progress. A safe and durable one-time treatment capable of lowering cholesterol for life could reshape public health on a global scale. Researchers believe such therapies may someday reduce heart attacks, strokes, hospitalizations, and healthcare costs while improving quality of life for countless patients. For now, experts encourage people to stay realistic, continue following proven prevention strategies, and understand that gene-editing medicine remains in the experimental stage. Yet optimism is growing because the science continues moving forward rapidly. What once sounded like a distant fantasy is increasingly becoming a serious medical possibility. The idea of preventing heart disease with a single treatment may not remain science fiction for much longer. (American Heart Association)
Key Points
Scientists are testing CRISPR-based gene-editing therapies to permanently lower cholesterol and reduce heart disease risk.
Experimental treatments target genes such as PCSK9 and ANGPTL3 that regulate cholesterol metabolism in the liver.
Early human trials showed LDL cholesterol reductions of around 50% after a single infusion.
Triglyceride levels also dropped significantly in some patients receiving treatment.
Researchers hope these therapies could eventually replace years of daily medication for certain high-risk patients.
Current studies remain small and experimental, meaning long-term safety and effectiveness are still unknown.
Scientists are carefully monitoring for unintended genetic changes and delayed side effects.
Patients with inherited cholesterol disorders may benefit most from future gene-editing therapies.
Traditional heart disease prevention methods including healthy diet, exercise, and prescribed medications remain essential today.
Experts believe gene editing could eventually transform preventive cardiology if future trials continue showing positive results.
Comments